0001209191-22-013983.txt : 20220301 0001209191-22-013983.hdr.sgml : 20220301 20220301161447 ACCESSION NUMBER: 0001209191-22-013983 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220225 FILED AS OF DATE: 20220301 DATE AS OF CHANGE: 20220301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Goncalves Joana CENTRAL INDEX KEY: 0001756991 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36279 FILM NUMBER: 22698173 MAIL ADDRESS: STREET 1: C/O CARA THERAPEUTICS, INC. STREET 2: 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL CITY: STAMFORD STATE: CT ZIP: 06902 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cara Therapeutics, Inc. CENTRAL INDEX KEY: 0001346830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4 STAMFORD PLAZA STREET 2: 107 ELM STREET 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06902 BUSINESS PHONE: 203-406-3700 MAIL ADDRESS: STREET 1: 4 STAMFORD PLAZA STREET 2: 107 ELM STREET 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06902 FORMER COMPANY: FORMER CONFORMED NAME: Cara Therapeutics Inc DATE OF NAME CHANGE: 20051213 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-02-25 0 0001346830 Cara Therapeutics, Inc. CARA 0001756991 Goncalves Joana C/O CARA THERAPEUTICS, INC. 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL STAMFORD CT 06902 0 1 0 0 Chief Medical Officer Common Stock 2022-02-25 4 A 0 20000 0.00 A 78507 D Common Stock 2022-02-25 4 S 0 1972 10.29 D 76535 D Employee Stock Option (Right to Buy) 10.46 2022-02-25 4 A 0 80000 0.00 A 2032-02-25 Common Stock 80000 80000 D Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in three equal annual installments on each of February 25, 2023, February 25, 2024 and February 25, 2025, in each case, subject to the Reporting Person's continued service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date. This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of RSUs reported in the Form 4 filed with the Securities and Exchange Commission on August 26, 2021, and does not represent a discretionary trade by the Reporting Person. The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on March 25, 2022, in each case subject to the Reporting Person's continued service as of each such date. /s/ Darren DeStefano, Attorney-in-Fact 2022-03-01